Faricimab在视网膜血管性疾病治疗中的应用  

Application of Faricimab in the treatment of retinal vascular diseases

作　　者：徐君 XU Jun(Fifth School of Clinical Medicine of Zhejiang Chinese Medical University(Huzhou Central Hospital),Huzhou 313000,Zhejiang Province,China)

机构地区：[1]浙江中医药大学第五临床医学院(湖州市中心医院),浙江省湖州市313000

出　　处：《眼科新进展》2024年第10期835-840,共6页Recent Advances in Ophthalmology

摘　　要：Faricimab是一种可同时抑制血管内皮生长因子-A和血管生成素-2的新型双特异性单抗。在已完成的临床研究中,Faricimab展现了优异的效果,包括提高患者视力、减少血管通透性和改善视网膜水肿等,且治疗的持久性优于阿柏西普与雷珠单抗。2022年1月28日,Faricimab由美国食品药品监督管理局批准上市,用于治疗新生血管年龄相关性黄斑变性和糖尿病性黄斑水肿,并于2023年10月26日新增视网膜静脉阻塞适应证。本文就Faricimab在视网膜血管性疾病中的疗效、应用前景以及局限性进行综述。Faricimab is a novel bispecific monoclonal antibody that simultaneously inhibits vascular endothelial growth factor-A and angiopoietin-2.In the completed clinical studies,Faricimab has demonstrated excellent efficacy in improving visual acuity,reducing vascular permeability and relieving retinal edema.Furthermore,the durability of the treatment is better than that of aflibercept and ranibizumab.On January 28,2022,Faricimab was approved for listing by the U.S.Food and Drug Administration for the treatment of neovascular age-related macular degeneration and diabetic macular edema.Additionally,on October 26,2023,retinal vein obstruction was approved as an expanded indication.This article discusses the efficacy,potential applications and limitations of Faricimab in retinal vascular diseases.

关 键 词：Faricimab 年龄相关性黄斑变性 糖尿病性黄斑水肿 视网膜静脉阻塞 

分 类 号：R774.1[医药卫生—眼科]